Hologic, Inc. (HOLX) Director Elaine Ullian Sells 9,282 Shares

Hologic, Inc. (NASDAQ:HOLX) Director Elaine Ullian sold 9,282 shares of the stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $40.50, for a total transaction of $375,921.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Hologic, Inc. (HOLX) traded down $1.02 during trading hours on Wednesday, reaching $39.62. 4,083,900 shares of the company were exchanged, compared to its average volume of 2,749,326. Hologic, Inc. has a 1-year low of $35.76 and a 1-year high of $46.80. The company has a market capitalization of $11,183.05, a price-to-earnings ratio of 20.12, a price-to-earnings-growth ratio of 1.96 and a beta of 0.93. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.78.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. The firm had revenue of $802.90 million for the quarter, compared to the consensus estimate of $792.54 million. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The business’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.52 earnings per share. analysts anticipate that Hologic, Inc. will post 2.12 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.truebluetribune.com/2017/11/15/hologic-inc-holx-director-elaine-ullian-sells-9282-shares.html.

Several equities analysts have recently weighed in on HOLX shares. Royal Bank Of Canada dropped their price objective on shares of Hologic from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research report on Thursday, August 3rd. BidaskClub lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Zacks Investment Research raised shares of Hologic from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Barclays PLC dropped their price objective on shares of Hologic from $53.00 to $51.00 and set an “overweight” rating on the stock in a research report on Thursday, August 3rd. Finally, Needham & Company LLC reissued a “buy” rating on shares of Hologic in a research report on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $47.54.

A number of institutional investors have recently made changes to their positions in HOLX. NN Investment Partners Holdings N.V. grew its stake in Hologic by 411.7% during the second quarter. NN Investment Partners Holdings N.V. now owns 9,477 shares of the medical equipment provider’s stock worth $430,000 after buying an additional 7,625 shares in the last quarter. State of Alaska Department of Revenue grew its stake in Hologic by 53.4% during the second quarter. State of Alaska Department of Revenue now owns 19,132 shares of the medical equipment provider’s stock worth $868,000 after buying an additional 6,660 shares in the last quarter. National Pension Service grew its stake in Hologic by 9.8% during the second quarter. National Pension Service now owns 268,334 shares of the medical equipment provider’s stock worth $12,204,000 after buying an additional 24,049 shares in the last quarter. Mn Services Vermogensbeheer B.V. grew its stake in Hologic by 595.5% during the second quarter. Mn Services Vermogensbeheer B.V. now owns 46,443 shares of the medical equipment provider’s stock worth $2,108,000 after buying an additional 39,765 shares in the last quarter. Finally, LS Investment Advisors LLC grew its stake in Hologic by 3.3% during the second quarter. LS Investment Advisors LLC now owns 13,314 shares of the medical equipment provider’s stock worth $604,000 after buying an additional 424 shares in the last quarter. Hedge funds and other institutional investors own 96.41% of the company’s stock.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply